{"id":564,"date":"2020-10-01T11:32:59","date_gmt":"2020-10-01T11:32:59","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=564"},"modified":"2020-10-01T11:32:59","modified_gmt":"2020-10-01T11:32:59","slug":"30-sep-2020-tocilizumab-corticosteroid-better-outcomes-in-older-patients-with-severe-covid","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/30-sep-2020-tocilizumab-corticosteroid-better-outcomes-in-older-patients-with-severe-covid\/","title":{"rendered":"(30 Sep 2020) Tocilizumab &#038; Corticosteroid- Better outcomes in older patients with severe COVID"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p id=\"page-title\" class=\"highwire-cite-title\">Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: a single-center retrospective study<\/p>\n<p>https:\/\/www.medrxiv.org\/content\/10.1101\/2020.09.26.20202283v1<\/p>\n<p class=\"\">A retrospective single center study including consecutive patients older than 65 years that developed severe COVID19 between March 3 and May 1, 2020 and were treated with corticosteroids at various doses (methylprednisolone [0.5 mg\/Kg\/12 hours to 250 mg\/24 hours]), either alone (CS group) or associated to intravenous tocilizumab (400 to 600 mg, one to three doses) (CS\/TCZ group) was conducted. Primary outcome was all cause mortality by day +14, whereas secondary outcomes included mortality by day +28 and clinical improvement (discharge and\/or a 2 point decrease on a six point ordinal scale) by day +14. Overall, 181 and 80 patients were included in the CS and CS TCZ groups. All cause 14 day mortality was lower in the CS\/TCZ group, both in the PS adjusted (hazard ratio [HR]: 0.34; 95% confidence interval [CI]: 0.17 to 0.68; P value = 0.002) and IPTW weighted models (odds ratio [OR]: 0.38; 95% CI: 0.21 to 0.68; P value = 0.001). This protective effect was also observed for 28 day mortality (PS adjusted HR: 0.38; 95% CI: 0.21 to 0.72; P value = 0.003). Clinical improvement by day +14 was higher in the CS\/TCZ group in the IPTW analysis only (OR: 2.26; 95% CI: 1.49 to 3.41; P value &lt;0.001). The occurrence of secondary infection was similar between both groups. The combination of corticosteroids and TCZ was associated with better outcomes among patients older than 65 years with severe COVID-19.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: a single-center retrospective study https:\/\/www.medrxiv.org\/content\/10.1101\/2020.09.26.20202283v1 A retrospective single center study including consecutive patients older than 65 years that developed severe COVID19 between March 3 and May 1,&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/30-sep-2020-tocilizumab-corticosteroid-better-outcomes-in-older-patients-with-severe-covid\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(30 Sep 2020) Tocilizumab &#038; Corticosteroid- Better outcomes in older patients with severe COVID&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[51,4,18],"tags":[52,27],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/564"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=564"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/564\/revisions"}],"predecessor-version":[{"id":565,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/564\/revisions\/565"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=564"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=564"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=564"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}